Egetis Therapeutics Past Earnings Performance
Past criteria checks 0/6
Egetis Therapeutics's earnings have been declining at an average annual rate of -27.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 4.1% per year.
Key information
-27.7%
Earnings growth rate
13.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -4.1% |
| Return on equity | -100.2% |
| Net Margin | -470.3% |
| Next Earnings Update | 26 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Egetis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 68 | -319 | 196 | -32 |
| 30 Jun 24 | 71 | -319 | 184 | -15 |
| 31 Mar 24 | 63 | -327 | 180 | -12 |
| 31 Dec 23 | 58 | -327 | 170 | 0 |
| 30 Sep 23 | 31 | -319 | 147 | 137 |
| 30 Jun 23 | 24 | -286 | 121 | 88 |
| 31 Mar 23 | 22 | -240 | 95 | 45 |
| 31 Dec 22 | 23 | -194 | 74 | 0 |
| 30 Sep 22 | 20 | -148 | 61 | 0 |
| 30 Jun 22 | 21 | -113 | 52 | 0 |
| 31 Mar 22 | 42 | -114 | 48 | 0 |
| 31 Dec 21 | 38 | -104 | 45 | 0 |
| 30 Sep 21 | 40 | -147 | 40 | 0 |
| 30 Jun 21 | 36 | -153 | 38 | 0 |
| 31 Mar 21 | 33 | -155 | 35 | 0 |
| 31 Dec 20 | 41 | -178 | 32 | 0 |
| 30 Sep 20 | 53 | -127 | 33 | 0 |
| 30 Jun 20 | 56 | -134 | 34 | 0 |
| 31 Mar 20 | 39 | -127 | 36 | 0 |
| 31 Dec 19 | 83 | -61 | 37 | 0 |
| 30 Sep 19 | 77 | -61 | 35 | 0 |
| 30 Jun 19 | 77 | -48 | 34 | 0 |
| 31 Mar 19 | 82 | -46 | 32 | 0 |
| 31 Dec 18 | 28 | -85 | 31 | 0 |
| 30 Sep 18 | 31 | -95 | 30 | 0 |
| 30 Jun 18 | 24 | -103 | 30 | 0 |
| 31 Mar 18 | 14 | -91 | 27 | 0 |
| 31 Dec 17 | 14 | -88 | 24 | 0 |
| 30 Sep 17 | 0 | -67 | 21 | 0 |
| 30 Jun 17 | 0 | -48 | 19 | 0 |
| 31 Mar 17 | 0 | -44 | 19 | 0 |
| 31 Dec 16 | 0 | -38 | 20 | 0 |
| 30 Sep 16 | 0 | -36 | 19 | 0 |
| 30 Jun 16 | 0 | -39 | 19 | 0 |
| 31 Mar 16 | 0 | -39 | 18 | 0 |
| 31 Dec 15 | 0 | -44 | 18 | 0 |
| 30 Sep 15 | 0 | -53 | 28 | 0 |
| 30 Jun 15 | 0 | -53 | 26 | 0 |
| 31 Mar 15 | 0 | -54 | 19 | 0 |
| 31 Dec 14 | 0 | -48 | 19 | 0 |
| 30 Sep 14 | 0 | -38 | 6 | 0 |
| 30 Jun 14 | 0 | -31 | 6 | 0 |
| 31 Mar 14 | 0 | -24 | 10 | 0 |
Quality Earnings: P0F is currently unprofitable.
Growing Profit Margin: P0F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: P0F is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.
Accelerating Growth: Unable to compare P0F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: P0F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: P0F has a negative Return on Equity (-100.22%), as it is currently unprofitable.